KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillAmortization of GoodwillCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in Working CapitalChange in Working CapitalDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Gains from Investment Securities (2016 - 2026)

Teva Pharmaceutical Industries filings provide 16 years of Gains from Investment Securities readings, the most recent being -$1.0 million for Q1 2026.

  • On a quarterly basis, Gains from Investment Securities changed N/A to -$1.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$6.0 million, a 200.0% decrease, with the full-year FY2025 number at -$5.0 million, down 150.0% from a year prior.
  • Gains from Investment Securities hit -$1.0 million in Q1 2026 for Teva Pharmaceutical Industries, up from -$2.0 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $4.0 million in Q4 2022 to a low of -$3.0 million in Q3 2022.
  • Median Gains from Investment Securities over the past 5 years was $0.0 (2022), compared with a mean of $0.0.
  • The widest YoY moves for Gains from Investment Securities: up 300.0% in 2023, down 125.0% in 2023.
  • Teva Pharmaceutical Industries' Gains from Investment Securities stood at $4.0 million in 2022, then tumbled by 125.0% to -$1.0 million in 2023, then plummeted by 100.0% to -$2.0 million in 2024, then changed by 0.0% to -$2.0 million in 2025, then soared by 50.0% to -$1.0 million in 2026.
  • The last three reported values for Gains from Investment Securities were -$1.0 million (Q1 2026), -$2.0 million (Q3 2025), and -$3.0 million (Q2 2025) per Business Quant data.